NASDAQ:INO Inovio Pharmaceuticals (INO) Stock Price, News & Analysis $1.66 +0.16 (+10.67%) Closing price 04:00 PM EasternExtended Trading$1.60 -0.05 (-3.31%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Inovio Pharmaceuticals Stock (NASDAQ:INO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Inovio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.47▼$1.6850-Day Range$1.50▼$2.2952-Week Range$1.48▼$13.44Volume844,292 shsAverage Volume562,386 shsMarket Capitalization$60.87 millionP/E RatioN/ADividend YieldN/APrice Target$12.20Consensus RatingModerate Buy Company OverviewInovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.Read More… Remove Ads Inovio Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreINO MarketRank™: Inovio Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 214th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingInovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageInovio Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Inovio Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($4.23) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inovio Pharmaceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inovio Pharmaceuticals is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInovio Pharmaceuticals has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Inovio Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.69% of the float of Inovio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently decreased by 3.08%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInovio Pharmaceuticals does not currently pay a dividend.Dividend GrowthInovio Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.01 Percentage of Shares Shorted14.69% of the float of Inovio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently decreased by 3.08%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentInovio Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Inovio Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest6 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows6 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.50% of the stock of Inovio Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.Read more about Inovio Pharmaceuticals' insider trading history. Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INO Stock News HeadlinesAnalysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $12.20March 29, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for INO Q1 EarningsMarch 23, 2025 | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)March 19, 2025 | markets.businessinsider.comInovio price target lowered to $5 from $6 at RBC CapitalMarch 19, 2025 | markets.businessinsider.comInovio reports Q4 EPS (65c), consensus (83c)March 19, 2025 | markets.businessinsider.comInovio price target lowered to $12 from $18 at Citizens JMPMarch 19, 2025 | markets.businessinsider.comInovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issuesMarch 19, 2025 | msn.comSee More Headlines INO Stock Analysis - Frequently Asked Questions How have INO shares performed this year? Inovio Pharmaceuticals' stock was trading at $1.83 at the beginning of the year. Since then, INO stock has decreased by 9.3% and is now trading at $1.66. View the best growth stocks for 2025 here. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its quarterly earnings results on Tuesday, March, 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.18. The biopharmaceutical company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.03 million. When did Inovio Pharmaceuticals' stock split? Inovio Pharmaceuticals's stock reverse split on Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Inovio Pharmaceuticals? Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX) and Pfizer (PFE). Company Calendar Last Earnings3/18/2025Today4/02/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:INO CIK1055726 Webwww.inovio.com Phone(267) 440-4200Fax267-440-4242Employees320Year Founded1979Price Target and Rating Average Stock Price Target$12.20 High Stock Price Target$20.00 Low Stock Price Target$3.00 Potential Upside/Downside+650.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,120,000.00 Net MarginsN/A Pretax Margin-55,315.44% Return on Equity-118.17% Return on Assets-83.47% Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.88 Sales & Book Value Annual Sales$217,756.00 Price / Sales273.80 Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book0.32Miscellaneous Outstanding Shares36,667,000Free Float25,448,000Market Cap$59.62 million OptionableOptionable Beta0.92 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (NASDAQ:INO) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.